Multicenter study of isavuconazole mic distributions and epidemiological cutoff values for the cryptococcus neoformans-cryptococcus gattii species complex using the clsi m27-a3 broth microdilution method

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 666-668

  Espinel Ingroff, A ^a   Chowdhary, A ^b   Gonzalez, G M ^c   Guinea, J ^d   Hagen, F ^e   Meis, J F ^e,f   Iii, G R Thompson ^g   Turnidgeh, J ^h  

^a VIRGINIA COMMONWEALTH UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF DELHI   (India)

^c UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ISAVUCONAZOLE; ANTIFUNGAL AGENT; NITRILE; PYRIDINE DERIVATIVE; TRIAZOLE DERIVATIVE;

ARTICLE; BROTH DILUTION; CLINICAL ARTICLE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FUNGUS GROWTH; FUNGUS ISOLATION; GENOTYPE; GROWTH INHIBITION; HUMAN; LABORATORY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; TREATMENT FAILURE; WILD TYPE; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; MICROBIAL SENSITIVITY TEST;

ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; GENOTYPE; HUMANS; MICROBIAL SENSITIVITY TESTS; NITRILES; PYRIDINES; TRIAZOLES;

EID: 84920132563     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04055-14     Document Type: Article

References (22)

1. Bovers M, Hagen F, Boekhout T. 2008. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species-complex. Rev Iberoam Micol 25: S4-S12. http://dx.doi.org/10.1016/S1130-1406(08)70019-6.
2. Harris JR, Lockhart SR, Debess E, Marsden-Haug N, Goldoft M, Wohrle R, Lee S, Smelser C, Park B, Chiller T. 2011. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 53:1188-1195. http://dx.doi.org/10.1093/cid/cir723.
3. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortharly O. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 50:291-322. http: //dx.doi.org/10.1086/649858.
4. Desnos-Ollivier M, Patel S, Spaulding AR, Charlier C, Garcia-Hermoso D, Nielsen K, Dromer F. 2010. Mixed infections and in vivo evolution in the human fungal pathogen Cryptococcus neoformans. mBio 1:e00091-10. http://dx.doi.org/10.1128/mBio.00091-10.
5. Byrnes EJ, Li W, Lewit Y, Ma H, Voelz K, Ren P, Carter DA, Chatuvedi D, Bildfell RJ. 2010. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog 6:e1000850. http://dx.doi.org/10.1371/journal.ppat.1000850.
6. Byrnes EJ, Wenjun L, Ren P, Lewit Y, Voelz K, Fraser J, Dietrich FS, May RC, Chatuvedi S, Chatuvedi D, Heitman J. 2011. A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients. PLoS Pathog 7:e1002205. http://dx.doi.org/10.1371 /journal.ppat.1002205.
7. Hagen F, Colom MF, Swinne D, Tintelnot K, Iatta R, Montagna MT, Torres-Rodriguez JM, Cogliati M, Velegraki A, Burggraaf A, Kamermans A, Sweere JM, Meis JF, Klaassen CH, Boekhout T. 2012. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg Infect Dis 18:1618-1624. http://dx.doi.org/10.3201/eid1810.120068.
8. Ostrosky-Zeichner L, Marr KA, Rex JH, Cohen SH. 2003. Amphotericin B: time for a new "gold standard." Clin Infect Dis 37:415-425. http://dx .doi.org/10.1086/376634.
9. Thompson GR, III, Wiederhold NP. 2010. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia 170: 291-313. http://dx.doi.org/10.1007/s11046-010-9324-3.
10. Clinical and Laboratory Standards Institute. 2014. Minutes and agenda: annual meeting of the Subcommittee for Antifungal Susceptibility Testing. San Antonio, TX, 11 January 2014.
11. Espinel-Ingroff A, Pfaller MA, Bustamante B, Canton E, Fothergill A, Fuller J, Gonzalez GM, Lass-Flörl C, Lockhart SR, Martin-Mazuelos E, Meis JF, Melhem MSC, Ostrosky-Zeichner L, Pelaez T, Szeszs MW, St-Germain G, Bonfietti LX, Guarro J, Turnidge J. 2014. Multilaboratory study of epidemiological cutoff values for detection of resistance in eight Candida species to fluconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 58:2006-2012. http://dx .doi.org/10.1128/AAC.02615-13.
12. Espinel-Ingroff A, Aller I, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Govender N, Hagen F, Illinait-Zaragoza MT, Johnson E, Kidd S, Lass-Flörl C, Lockhart SR, Martins MA, Meis JF, Melhem MSC, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidg Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values fluconazole, itraconazole, posaconazole, and voriconazole Antimicrob Agents Chemother 56 5898-5906 http: //dx.doi.org/10.1128/AAC.01115-12 Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob Agents Chemother 56:5898-5906. http: //dx.doi.org/10.1128/AAC.01115-12.
13. Turnidge J, Kahmeter G, Kronvall G. 2006. Statistical characterization of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values. Clin Microbiol Infect 12:418-425. http://dx .doi.org/10.1111/j.1469-0691.2006.01377.x.
14. rd ed. CLSI document M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
15. Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, Sun S, Xu J. 2011. In vitro antifungal susceptibilities and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and C. gattii serotype B from North West India. J Med Microbiol 60:961-967. http://dx.doi.org/10.1099/jmm.0.029025-0.
16. Guinea J, Hagen F, Pelaez T, Boekhout T, Tahoune H, Torres-Narbona M, Bouza E. 2010. Antifungal susceptibility, serotyping, and genotyping of clinical Cryptococcus neoformans isolates collected during 18 years in a single institution in Madrid, Spain. Med Mycol 48:942-948. http://dx.doi .org/10.3109/13693781003690067.
17. Hagen F, Illnait-Zaragozi MT, Meis JF, Chew WHM, Curfs-Breuker I, Mouton JW, Hoepelman AI, Spanjaard L, Verweij PE, Kampinga GA, Kuijper EJ, Boekhout T, Klaassen CHW. 2012. Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population. J Clin Microbiol 50:1918-1926. http://dx.doi.org/10.1128/JCM.06750-11.
18. Hagen F, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsen E, Klaassen CH, Boekhout T, Meis JF. 2010. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 54:5139-5149. http://dx .doi.org/10.1128/AAC.00746-10.
19. Thompson GR, III, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob Agents Chemother 53:309-311. http://dx.doi.org/10.1128/AAC.01216-08.
20. Turnidge J, Paterson DL. 2007. Setting and revising antibacterial susceptibility breakpoints. Clin Microbiol Rev 20:391-408. http://dx.doi.org/10 .1128/CMR.00047-06.
21. Dalhoff A, Ambrose PG, Mouton JW. 2009. A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints. Infection 37: 296-305. http://dx.doi.org/10.1007/s15010-009-7108-9.
22. Pfaller MA, Messer SA, Rhomberg PR, Jones RN, Castanheira M. 2013. In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds. J Clin Microbiol 51:2608-2616. http://dx.doi.org/10.1128/JCM.00863-13.